Equity Overview
Price & Market Data
Price: $13.63
Daily Change: +$0.08 / 0.59%
Daily Range: $13.62 - $14.49
Market Cap: $1,618,429,568
Daily Volume: 1,749,932
Performance Metrics
1 Week: 7.83%
1 Month: -0.48%
3 Months: 42.07%
6 Months: -32.70%
1 Year: 120.1%
YTD: 53.77%
Company Details
Employees: 377
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.